Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Spotlight on Clinical Response

Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates

Scott E. Woodman, Jonathan C. Trent, Katherine Stemke-Hale, Alexander J. Lazar, Sabrina Pricl, Giovanni M. Pavan, Maurizio Fermeglia, Y.N. Vashisht Gopal, Dan Yang, Donald A. Podoloff, Doina Ivan, Kevin B. Kim, Nicholas Papadopoulos, Patrick Hwu, Gordon B. Mills and Michael A. Davies
Scott E. Woodman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan C. Trent
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katherine Stemke-Hale
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander J. Lazar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sabrina Pricl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giovanni M. Pavan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maurizio Fermeglia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Y.N. Vashisht Gopal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dan Yang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald A. Podoloff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Doina Ivan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin B. Kim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas Papadopoulos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Hwu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gordon B. Mills
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael A. Davies
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-09-0459 Published August 2009
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    L576P KIT mutation in a melanoma cell line. A, mass spectroscopy-based detection of the L576P KIT mutant allele(s) in the WM3211 cell line. A peak is correlated with the L576P mutant KIT (Mut), whereas there is no peak for the wild-type KIT (WT). B, sanger sequencing of exon 11 of KIT in the WM3211 cells. Arrow, T-to-C base pair change.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Effect of KIT inhibitors on WM3211 cell line viability. WM3211 (♦), MEWO (▪), and A375 (▴) human melanoma cells were treated with increasing doses of the KIT inhibitors, A, imatinib, B, sorafenib, C, nilotinib, or D, dasatinib, x-axis, drug concentration (nM); y-axis, percent reduction in cell viability. Each data point represents the average of three replicates, error bars represent the standard deviation.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Effects of L576P KIT mutation on protein structure and drug binding. The interaction of imatinib with A, wild-type versus B, L576P KIT reveals a ΔΔGbind = −2.52 kcal/mol, reflecting a decrease in affinity induced by the mutation. The interaction of dasatinib with C, wild-type versus D, L576P KIT reveals a ΔΔGbind = +0.32 kcal/mol. The free binding energy for L576P KIT is more favorable for dasatinib (−9.93 kcal/mole) than for imatinib (−7.75 kcal/mole), indicating a greater affinity for dasatinib.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Treatment of L576P KIT mucosal melanoma patients with dasatinib. FDG-PET/CT images of Patient A, A and B, and Patient B, C–F, metastatic mucosal melanoma patients, with L576P KIT mutant tumors. Images were obtained before, A, C, E, and after, B, D, F, treatment with 70 mg twice daily of dasatinib for 1 mo. Solid block white arrows indicate FDG-avid tumors; narrow white arrows indicate physiologic FDG excretion in renal collecting system.

Additional Files

  • Figures
  • Supplementary Data, Woodman, et al.

    Files in this Data Supplement:

    • Supplementary Table, Materials and References
PreviousNext
Back to top
Molecular Cancer Therapeutics: 8 (8)
August 2009
Volume 8, Issue 8
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates
Scott E. Woodman, Jonathan C. Trent, Katherine Stemke-Hale, Alexander J. Lazar, Sabrina Pricl, Giovanni M. Pavan, Maurizio Fermeglia, Y.N. Vashisht Gopal, Dan Yang, Donald A. Podoloff, Doina Ivan, Kevin B. Kim, Nicholas Papadopoulos, Patrick Hwu, Gordon B. Mills and Michael A. Davies
Mol Cancer Ther August 1 2009 (8) (8) 2079-2085; DOI: 10.1158/1535-7163.MCT-09-0459

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates
Scott E. Woodman, Jonathan C. Trent, Katherine Stemke-Hale, Alexander J. Lazar, Sabrina Pricl, Giovanni M. Pavan, Maurizio Fermeglia, Y.N. Vashisht Gopal, Dan Yang, Donald A. Podoloff, Doina Ivan, Kevin B. Kim, Nicholas Papadopoulos, Patrick Hwu, Gordon B. Mills and Michael A. Davies
Mol Cancer Ther August 1 2009 (8) (8) 2079-2085; DOI: 10.1158/1535-7163.MCT-09-0459
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Intratumoral Molecular Heterogeneity
  • Erlotinib Response EGFR+ NSCLC with Squamous Element
  • Chondrosarcoma and TRAIL Targeted Therapy
Show more Spotlight on Clinical Response
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement